Jun 25, 2020
Dr. Edith Perez, Chief Medical Officer, Bolt Biotherapeutics discusses an innovative new platform for the treatment of patients with cancer. The Boltbody™ platform uses a combination of tumor targeting antibodies and localized stimulation of the immune system, or immune stimulating antibody conjugates, to fight cancer. Bolt's preclinical data show that in addition to killing the tumor, there is an immunological memory which helps to prevent tumors from growing back. Dr. Perez also discusses Bolt's first target HER2-expressing cancers, how the Boltbody™ platform is overcoming challenges treating this cancer and Bolt's current Phase 1 clinical trial.
@BoltBio #HER2 #Cancer #Boltbody